Exercise-related breathing limits in adults with cystic fibrosis taking Elexacaftor‑Tezacaftor‑Ivacaftor
Official title: Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
Run by University Hospital, Lille · NCT07314229 · Data updated 2026-11-12
We will test how often adults with cystic fibrosis who are taking Elexacaftor‑Tezacaftor‑Ivacaftor reach ventilatory limits during a six‑minute walk.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | December 17, 2025 |
| Main results expected | February 2, 2027 |
| Study ends | April 4, 2027 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT07314229 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with cystic fibrosis who are treated with ETI and followed at the CRCM centers in Lille or Créteil, able to perform a six‑minute walk and give informed consent are ideal candidates.
✕Probably not a fit
Children, people not on ETI, those unable to perform exercise testing (including recent exacerbation or contraindications), pregnant or breastfeeding women, and those not treated at the participating centers are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional protocol enrolls adults with cystic fibrosis on ETI at CF centers in Lille and Créteil to measure breathing responses during a standard six‑minute walk test. Participants will have continuous ventilation and inspiratory capacity measured during the test and airway resistance measured by forced oscillation. The main goal is to estimate the prevalence of ventilatory reserve loss (ventilatory limitation) during submaximal exercise in this treated population. Standard contraindications to exercise testing and recent exacerbations are used to exclude participants.
Why it matters
Potential benefit: If successful, the results could help clinicians identify patients who need targeted breathing or exercise rehabilitation to improve daily activity and quality of life.
How similar studies have gone: Prior studies show ETI improves lung function and symptoms, but few have specifically measured ventilatory limitation during submaximal exercise, so this question remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female * Adult aged 18 or over * Suffering from cystic fibrosis * Treated at the CRCM in Lille and Créteil * Treated by ETI * Be covered by social security * Be able to understand the requirements of the study, provide written informed consent, and comply with the study's data collection procedures Exclusion Criteria: * Medical contraindication or inability to perform a stress test according to ERS recommendations * Absolute contraindications * Relative contraindications: * Exacerbation of the condition in the 4 weeks preceding the V1 visit (27). * Pregnant or breastfeeding women * Administrative reasons * Persons deprived of their liberty * Minors or protected adults * Persons who have refused or are unable to give informed consent * Persons in emergency situations
Where it's running
-
University Hospital
Lille, France Recruiting
Study contacts
- Study coordinator: Camille AUDOUSSET, Doctor
- Email: DRC@chu-lille.fr
- Phone: +33 3.20.44.41.45
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Household water and home environments as sources of non-tuberculous mycobacteria in people with cystic fibrosis
This study will test whether household water, dust, and soil carry non-tuberculous mycobacteria that could infect people with cystic fibrosis.
-
Oropharyngeal suction and physiotherapy to detect lung bacteria in kids with chronic lung disease
A randomized study will test whether taking samples from the throat with suction, with or without prior physiotherapy, can reliably detect bacteria in children 5–18 with chronic lung disease, compared with standard sample methods.
-
Seeing if CFTR functioncan be restored in CF through patient cells with rare mutations
This study tests whether testing a patient’s own nasal cells in the lab can predict if CFTR-modulator therapies might help people with uncommon CF mutations.
-
Perceptions and Intentions Around a Change in CF Treatment
This study asks adults with cystic fibrosis currently on ETI whether they would switch to VTD if their doctor offered it and what factors influence that decision.
-
How the CF medicines elexacaftor, tezacaftor, and ivacaftor behave in the body
This study tests how the CF medicines elexacaftor, tezacaftor, and ivacaftor move through the body in patients with cystic fibrosis who are already taking the combination therapy.
-
Autogenic Drainage vs. Mechanical Chest Percussion in Children with Cystic Fibrosis
In children aged 6-12 with cystic fibrosis, this study tests whether autogenic drainage helps lung function and comfort more than mechanical percussion.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.